All In Biotech

Drug Trial Radar · NCT07152288

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment

A Single-dose, Open-label, Phase I Study Comparing the Pharmacokinetics, Safety, and Pharmacodynamics of HSK39297 in Subjects With Mild and Moderate Hepatic Impairment and Normal Hepatic Function

Last checked: Nov 20, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

May 29, 2025

Primary completion

Sep 2025

Study completion Nov 2025

Sponsor

Sponsor type
Industry
First posted
Sep 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is being conducted to compare the pharmacokinetics, safety, and pharmacodynamics of HSK39297 in subjects with mild to moderate hepatic impairment and normal hepatic function

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

  • HSK39297 tabletsDrug

    oral

  • HSK39297 tabletsDrug

    oral

  • HSK39297 tabletsDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: Post-dose at day 1 to day 10.
  2. AUC0-tTime frame: Post-dose at day 1 to day 10
  3. AUC0-infTime frame: Post-dose at day 1 to day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.